Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company, has received approval from China’s National Medical Products Administration (NMPA) to initiate a Phase Ib/III clinical study. The study will evaluate the combination of Hengrui’s PD-L1 monoclonal antibody, adebrelimab (SHR-1316), with the antibody-drug conjugate (ADC) SHR-A1904 in patients with CLDN18.2 positive advanced solid tumors .
Adebrelimab, which has been previously approved in China for the treatment of first-line extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy, will be investigated alongside SHR-A1904. SHR-A1904 is an ADC that incorporates a topoisomerase inhibitor (TOPOi) payload and is currently in Phase I clinical trials in China, the US, and Australia .
This development highlights Hengrui’s commitment to advancing innovative treatments for patients with advanced solid tumors, leveraging the potential synergistic effects of immunotherapy and targeted drug delivery systems.- Flcube.com
